# Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease

> **NCT00250679** · PHASE3 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 443 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease
- Bronchitis
- Emphysema

## Interventions

- **DRUG:** Arformoterol tartrate inhalation solution
- **DRUG:** Arformoterol 25 ųg BID
- **DRUG:** Formoterol 12 ųg BID
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00250679
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 443 (ACTUAL)
- **Last updated:** 2012-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00250679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00250679, "Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00250679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*